Relmada Therapeutics (RLMD) Fundamentals 2026 — Revenue Analysis | SniperIQ
Relmada Therapeutics (RLMD) is a US-listed Healthcare company in Biotechnology with a market capitalization of $522M, trading at $4.97 on the NASDAQ. This SniperIQ fundamentals page covers Relmada Therapeutics's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Relmada Therapeutics's market cap?
Relmada Therapeutics (RLMD) has a market capitalization of approximately $522M, trading at $4.97 on the NASDAQ. Market cap moves with the live share price.
What is Relmada Therapeutics's P/E ratio?
Relmada Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Relmada Therapeutics?
Relmada Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Relmada Therapeutics pay a dividend?
Relmada Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Relmada Therapeutics financially healthy?
Relmada Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 18.26x, with a market beta of 0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Relmada Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Relmada Therapeutics (RLMD) the key facts are: market cap $522M, 52-week range 0.55-8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Relmada Therapeutics's full fundamentals live
Get Relmada Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.